Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen
Frederik N Engsig1, Jan Gerstoft1, Gitte Kronborg2, Carsten S Larsen3, Gitte Pedersen4, Anne M Audelin5, Louise B Jørgensen5, Niels Obel11Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark; 2Department of Infectious Diseases, Copenhagen Universi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-05-01
|
| Series: | Clinical Epidemiology |
| Online Access: | http://www.dovepress.com/clinical-virological-and-immunological-responses-in-danish-hiv-patient-a4504 |
| _version_ | 1819038080201392128 |
|---|---|
| author | Frederik N Engsig Jan Gerstoft Gitte Kronborg et al |
| author_facet | Frederik N Engsig Jan Gerstoft Gitte Kronborg et al |
| author_sort | Frederik N Engsig |
| collection | DOAJ |
| description | Frederik N Engsig1, Jan Gerstoft1, Gitte Kronborg2, Carsten S Larsen3, Gitte Pedersen4, Anne M Audelin5, Louise B Jørgensen5, Niels Obel11Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark; 2Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark; 3Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; 4Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark; 5Department of Virology, Statens Serum Institute, Copenhagen, DenmarkBackground: Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses.Methods: From a Danish population-based nationwide cohort of HIV patients we identified the individuals who initiated a salvage regimen including raltegravir and a matched cohort of HIV-infected patients initiating HAART for the first time. We compared these two cohorts for virological suppression, gain in CD4 count, and time to first change of initial regimen.Results: We identified 32 raltegravir patients and 64 HIV patients who initiated HAART for the first time in the period 1 January 2006 to 1 July 2009. The virological and immunological responses in the raltegravir patients were comparable to those seen in the control cohort. No patients in the two cohorts died and no patients terminated raltegravir treatment in the observation period. Time to first change of initial regimen was considerably shorter for HAART-naïve patients.Conclusion: We conclude that salvage regimens including raltegravir have high effectiveness in the everyday clinical setting. The effectiveness of the regimens is comparable to that observed for patients initiating HAART for the first time. The risk of change in the salvage regimens after initiation of raltegravir is low.Keywords: HIV, raltegravir, salvage regime, efficacy, matched cohort |
| first_indexed | 2024-12-21T08:31:37Z |
| format | Article |
| id | doaj.art-189a1036eec049ea974cd4d1a68f7df2 |
| institution | Directory Open Access Journal |
| issn | 1179-1349 |
| language | English |
| last_indexed | 2024-12-21T08:31:37Z |
| publishDate | 2010-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Epidemiology |
| spelling | doaj.art-189a1036eec049ea974cd4d1a68f7df22022-12-21T19:10:10ZengDove Medical PressClinical Epidemiology1179-13492010-05-012010default145151Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimenFrederik N EngsigJan GerstoftGitte Kronborget alFrederik N Engsig1, Jan Gerstoft1, Gitte Kronborg2, Carsten S Larsen3, Gitte Pedersen4, Anne M Audelin5, Louise B Jørgensen5, Niels Obel11Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark; 2Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark; 3Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; 4Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark; 5Department of Virology, Statens Serum Institute, Copenhagen, DenmarkBackground: Raltegravir is the first integrase inhibitor approved for treatment of HIV-infected patients harboring multiresistant viruses.Methods: From a Danish population-based nationwide cohort of HIV patients we identified the individuals who initiated a salvage regimen including raltegravir and a matched cohort of HIV-infected patients initiating HAART for the first time. We compared these two cohorts for virological suppression, gain in CD4 count, and time to first change of initial regimen.Results: We identified 32 raltegravir patients and 64 HIV patients who initiated HAART for the first time in the period 1 January 2006 to 1 July 2009. The virological and immunological responses in the raltegravir patients were comparable to those seen in the control cohort. No patients in the two cohorts died and no patients terminated raltegravir treatment in the observation period. Time to first change of initial regimen was considerably shorter for HAART-naïve patients.Conclusion: We conclude that salvage regimens including raltegravir have high effectiveness in the everyday clinical setting. The effectiveness of the regimens is comparable to that observed for patients initiating HAART for the first time. The risk of change in the salvage regimens after initiation of raltegravir is low.Keywords: HIV, raltegravir, salvage regime, efficacy, matched cohorthttp://www.dovepress.com/clinical-virological-and-immunological-responses-in-danish-hiv-patient-a4504 |
| spellingShingle | Frederik N Engsig Jan Gerstoft Gitte Kronborg et al Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen Clinical Epidemiology |
| title | Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen |
| title_full | Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen |
| title_fullStr | Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen |
| title_full_unstemmed | Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen |
| title_short | Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen |
| title_sort | clinical virological and immunological responses in danish hiv patients receiving raltegravir as part of a salvage regimen |
| url | http://www.dovepress.com/clinical-virological-and-immunological-responses-in-danish-hiv-patient-a4504 |
| work_keys_str_mv | AT frederiknengsig clinicalvirologicalandimmunologicalresponsesindanishhivpatientsreceivingraltegraviraspartofasalvageregimen AT jangerstoft clinicalvirologicalandimmunologicalresponsesindanishhivpatientsreceivingraltegraviraspartofasalvageregimen AT gittekronborg clinicalvirologicalandimmunologicalresponsesindanishhivpatientsreceivingraltegraviraspartofasalvageregimen AT etal clinicalvirologicalandimmunologicalresponsesindanishhivpatientsreceivingraltegraviraspartofasalvageregimen |